Zydus Lifesciences, a leading pharmaceutical company, has made a significant move by acquiring the UK-based LiqMeds Group, a specialist in oral liquid products, in an all-cash deal amounting to GBP 68 million (approximately INR 690 crores).

The acquisition, announced on Tuesday, is expected to bolster Zydus Lifesciences' presence and capabilities in the pharmaceutical industry.

As part of this strategic acquisition, Zydus will make an upfront payment of GBP 68 million, with additional yearly earn-outs until 2026 based on the achievement of certain predetermined milestones associated with the acquisition of LiqMeds Group, Economic Times reported.

Notably, this transaction is anticipated to be earnings per share (EPS) accretive for Zydus from the very first year following the acquisition.

The entire acquisition process is slated to be completed within 10 working days from the date of execution, emphasizing the company's commitment to swift and efficient integration.

One of the key assets acquired through this deal is LiqMeds Group's oral liquids manufacturing site located in Weedon, Northampton, UK. This facility plays a crucial role in supplying products to both the US and UK markets.

LiqMeds Group, with a turnover of GBP 5.3 million in 2022, is renowned for its expertise and specialization in the development, manufacturing, and supply of oral liquid products tailored for global markets.

Currently, the company commercializes these products through partnerships with various entities.

Sharvil Patel, the Managing Director of Zydus Lifesciences, commented on the acquisition, stating, "We believe that liquid orals is a large, growing market and serves unmet needs with significant new market expansion opportunities."

He also highlighted the patient-centric approach, emphasizing the positive impact of oral liquid formulations on geriatric and pediatric patients, providing them with enhanced convenience and therapy compliance.

This strategic acquisition marks a significant step for Zydus Lifesciences as it strengthens its position in the pharmaceutical industry, expands its product portfolio, and enhances its ability to cater to diverse patient needs across international markets.

The move aligns with the company's mission to provide innovative and accessible healthcare solutions.